ArticlePloS one2026
Streamlining recombinant peptide and protein production using a pre-configured elastin-like polypeptide expression cassette.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elastin-like polypeptides (ELPs) are synthetic biopolymers that exhibit a unique thermo-responsive behavior: they remain soluble below a defined transition temperature but undergo reversible aggregation when the temperature exceeds this threshold. This property enables a simplified, non-chromatographic protein purification strategy. Despite these advantages, ELP-based purification has not yet been widely adopted as a standard method in research laboratories, indicating that certain practical limitations or challenges remain to be addressed. The first major challenge is the absence of a standardized ELP-tagged protein expression cassette suitable for use in research laboratories. The second is the development of an effective strategy for purifying the target protein released from the ELP tag following enzymatic cleavage. In this study, we present an optimized and modular gene cassette designed to standardize ELP-tagged peptide that can operates under mild conditions, featuring a low inverse transition temperature (Tt) of 27-31 °C, reduced salt concentrations (up to 0.5 M NaCl), and produces high yield and high purity product. Additionally, we exploited the ELP's concentration induced aggregation to facilitate its separation from the target protein by filtration following enzymatic cleavage to address the second challenge. Here, we emphasize that this protocol has proven to be particularly efficient for the purification of small peptides, primarily due to the substantial size difference between the target peptide and the ELP tag. The purification of larger peptides remains feasible but may require alternative purification strategies. As a case study, we illustrate the purification of human β-defensin 1 (hBD-1; gene DEFB1), a 36-residue antimicrobial peptide, and discuss the challenges encountered and solutions implemented during the purification process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.